Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

CDC25B mediates rapamycin-induced oncogenic responses in cancer cells.

Chen RQ, Yang QK, Lu BW, Yi W, Cantin G, Chen YL, Fearns C, Yates JR 3rd, Lee JD.

Cancer Res. 2009 Mar 15;69(6):2663-8. doi: 10.1158/0008-5472.CAN-08-3222. Epub 2009 Mar 10.

2.

Determinants of rapamycin sensitivity in breast cancer cells.

Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F.

Clin Cancer Res. 2004 Feb 1;10(3):1013-23.

3.

Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.

Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.

Clin Cancer Res. 2004 Oct 15;10(20):6779-88.

4.

Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells.

Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J, Rozengurt E.

PLoS One. 2013;8(2):e57289. doi: 10.1371/journal.pone.0057289. Epub 2013 Feb 21.

5.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR.

Cancer Res. 2005 Aug 15;65(16):7052-8.

6.

Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.

Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, Troyer DA, Kreisberg JI.

Endocr Relat Cancer. 2005 Mar;12(1):119-34.

7.

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.

Clin Cancer Res. 2004 Dec 1;10(23):8059-67.

8.

Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.

Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.

Oncogene. 2007 Aug 16;26(38):5606-14. Epub 2007 Mar 12.

PMID:
17353907
9.

Lipin-1 regulates cancer cell phenotype and is a potential target to potentiate rapamycin treatment.

Brohée L, Demine S, Willems J, Arnould T, Colige AC, Deroanne CF.

Oncotarget. 2015 May 10;6(13):11264-80.

10.

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.

Mol Cancer Ther. 2010 Apr;9(4):963-75. doi: 10.1158/1535-7163.MCT-09-0763. Epub 2010 Apr 6.

11.

Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling.

He X, Wang Y, Zhu J, Orloff M, Eng C.

Cancer Lett. 2011 Feb 28;301(2):168-76. doi: 10.1016/j.canlet.2010.11.012. Epub 2010 Dec 17.

PMID:
21168265
12.

Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.

Wang X, Yue P, Chan CB, Ye K, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Fu H, Khuri FR, Sun SY.

Mol Cell Biol. 2007 Nov;27(21):7405-13. Epub 2007 Aug 27.

14.

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.

Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY.

Cancer Res. 2008 Sep 15;68(18):7409-18. doi: 10.1158/0008-5472.CAN-08-1522.

15.

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S.

Cancer Res. 2005 Apr 15;65(8):3336-46.

16.

G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.

Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH.

Am J Physiol Cell Physiol. 2004 Aug;287(2):C281-91. Epub 2004 Mar 17.

17.

Rapamycin promotes vascular smooth muscle cell differentiation through insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt2 feedback signaling.

Martin KA, Merenick BL, Ding M, Fetalvero KM, Rzucidlo EM, Kozul CD, Brown DJ, Chiu HY, Shyu M, Drapeau BL, Wagner RJ, Powell RJ.

J Biol Chem. 2007 Dec 7;282(49):36112-20. Epub 2007 Sep 30.

19.

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.

Yori JL, Lozada KL, Seachrist DD, Mosley JD, Abdul-Karim FW, Booth CN, Flask CA, Keri RA.

Cancer Res. 2014 Sep 1;74(17):4762-71. doi: 10.1158/0008-5472.CAN-13-3627. Epub 2014 Jul 14.

20.

mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.

Liu J, Stevens PD, Gao T.

J Biol Chem. 2011 Feb 25;286(8):6510-20. doi: 10.1074/jbc.M110.183087. Epub 2010 Dec 22.

Supplemental Content

Support Center